



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-18

BOTTAZZI et al.

C# M#

Serial No. 09/555,473

Group Art Unit: 1644

Examiner: Jamroz

Filed: February 26, 2002

Date: March 20, 2002

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN  
PTX3

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED

MAR 21 2002

TECH CENTER 1600/2900

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered , filed

☐ Submission attached

**Subtotal \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Abstract; The Merck Index, Eleventh Edition, page 278, point 1835 0.00

Copy of previously submitted PTO-1449; copy of

Submission of Priority Documents dated 1/29/02

and copy of postcard receipt of 1/29/02


**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:eaw

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature:



#16 C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ES, 4/1/03

In re Patent Application of

**BOTTAZZI et al.**

Atty. Ref.: **2801-18**

Serial No. **09/555,473**

Group: **1644**

Filed: **February 26, 2002**

Examiner: **Jamroz**

For: **PHARMACEUTICAL COMPOSITIONS CONTAINING THE  
LONG PENTRAXIN PTX3**

\* \* \* \* \*

**RECEIVED**

**March 20, 2002**

**MAR 21 2002**

Assistant Commissioner for Patents  
Washington, DC 20231

**TECH CENTER 1600/2900**

Sir:

**AMENDMENT**

Responsive to the Official Action dated December 20, 2001, entry and  
consideration of the following amendments and remarks are requested.

**IN THE ABSTRACT**

Insert the attached Abstract after the claims pages.

**IN THE SPECIFICATION**

Amend the specification as follows.

Page 12, between lines 3 and 4, insert the following paragraph:

--Figure 1: Schematic representation of the cDNA fragment coding for the  
human PTX3 protein subcloned in the Bam H1 site of pSG5 expression vector. The two  
domains (N-terminal and C-terminal or pentraxin like) are indicated: the pentraxin like

C<sup>1</sup>